Arcadia Pharmaceutical Stock Price
Listing Websites about Arcadia Pharmaceutical Stock Price
› Myuhcmedicare.com hwp sign in
› 2022 wellcare act mastery exam quizlet
› Myuhcmedicare com hwp products catalog 2022
› Medicines and healthcare products regulatory
› Myuhcmedicare hwp catalog online
› United healthcare otc order online
› New bedford ma board of health
› Griffin hospital ct medical records
› West ward pharmaceuticals stock
› Aetna medicaid drug formulary 2022
Recently Searched› Arcadia pharmaceutical stock price
› Approved medical abbreviations jcaho 2020
› Cdl license drug testing requirements
› Does medicare pay for an annual physical
› Valley medical center kent wa
› Pharmacy assistant course online
FAQ about Arcadia Pharmaceutical Stock Price
Who owns Acadia Pharmaceuticals stock?
Company insiders that own ACADIA Pharmaceuticals stock include Austin D Kim, Austin D Kim, Bros Advisors Lp Baker, Elena Ridloff, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis. View institutional ownership trends for ACADIA Pharmaceuticals.
How much is a share of Acadia worth?
One share of ACAD stock can currently be purchased for approximately $22.26. How much money does ACADIA Pharmaceuticals make? ACADIA Pharmaceuticals has a market capitalization of $3.58 billion and generates $441.76 million in revenue each year.
What are analysts'price targets for Acadia Pharmaceuticals (Acadia)?
19 Wall Street analysts have issued 12-month price objectives for ACADIA Pharmaceuticals' shares. Their forecasts range from $18.00 to $57.00. On average, they expect ACADIA Pharmaceuticals' stock price to reach $28.60 in the next twelve months. This suggests a possible upside of 28.5% from the stock's current price.
How did Acadia’s (ACAD) stock perform in after-hours trading?
Resultantly, its shares rise in after-hours trading. Acadia (ACAD) delivered earnings and revenue surprises of 66.67% and 3.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?